Indi Molecular® has developed synthetic small molecule targeted oncology therapeutics against overexpressed folate receptors in ovarian cancer and KRAS G12D expressing pancreatic cancers.  We created these therapeutic molecules using a breakthrough, synthetic protein chemistry platform: Protein Catalyzed Capture (PCC) agents. These targeted therapeutics are small synthetic peptide replacements for antibody-based therapeutics. 

Indi 177Lu-7327 is an ultra-high affinity folate receptor targeting molecule that exerts its effect in folate receptor overexpressing cancers by the precision delivery of its therapeutic 177Lu payload.  This molecule possess a unique 177Lu renal-sparing property that permits higher tolerated therapeutic dosing.  The Indi 177Lu-7327 molecule was recently the subject of an FDA pre-IND review.

Indi-344 targets mutated KRAS G12D in pancreatic cancer cells.  This cyclic peptide efficiently penetrates the cell’s plasma membrane and localizes on the membrane’s interior surface. Indi-344 binds to the mutated KRAS G12D oncogene’s switch region and inhibits its function.

SPECIFICITY

Specific to the chosen epitope of the desired target protein

Affinity

Pico-molar and low nano-molar binding affinities with demonstrable cooperative binding for affinity enhancement

SOLUBLE

D-amino acids yield stable molecules, retain good water solubility and are renally cleared

Tunable

Fully synthetic small peptides for rapid synthesis and robust manufacturing

SPEED

Go from an identified epitope to nanomolar binding affinity in 4 weeks

IN VIVO

PCC have demonstrated in vivo functional activity and can deliver a therapeutic effect against both intra and extracellular targets

Recent News